Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonucleotide reductase class III catalyzes the conversion of ribonucleotides to deoxyribonucleotides, providing the building blocks required for DNA synthesis in anaerobic bacteria[7]. This enzyme is a glycyl radical protein that operates under strictly anaerobic conditions, using formate or similar electron donors and is oxygen-sensitive. It is essential for bacterial proliferation and is absent in human cells, positioning it as a potential selective antibacterial drug target. There are other supporting enzymes and systems involved in bacterial DNA synthesis, such as DNA polymerases, helicases, and regulatory proteins (like DnaA for origin unwinding[1]), but RNR class III serves as the canonical, defining enzyme for anaerobic deoxyribonucleotide production[7].
Inhibition leads to depletion of deoxyribonucleotide pools, halting DNA synthesis and cell division[7]. Some inhibitors irreversibly inactivate the glycyl radical essential for class III enzyme function (theoretically applies).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleotide reductase class III (RNR class III).